ReviewHuman gene therapy2010
Cardiac gene therapy: optimization of gene delivery techniques in vivo.
Review in Human gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep.Gene therapy · 2025Article
- Recent advances in gene therapy for atrial fibrillation.Journal of cardiovascular electrophysiology · 2021Review
- Gene therapy for atrial fibrillation - How close to clinical implementation?International journal of cardiology · 2019Review
- Gene Therapy for the Treatment of Cardiac Arrhythmias: Current and Emerging Applications.The Journal of innovations in cardiac rhythm management · 2018Review
- Technique of Complete Heart Isolation with Continuous Cardiac Perfusion During Cardiopulmonary Bypass: New Opportunities for Gene Therapy.The journal of extra-corporeal technology · 2018Article
- Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure.Human gene therapy. Clinical development · 2017Review
- Article
- Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.Wiley interdisciplinary reviews. Systems biology and medicine · 2017Review
- Somatic Cell Reprogramming into Cardiovascular Lineages.Journal of cardiovascular pharmacology and therapeutics · 2014Article
- Gene therapy to treat cardiovascular disease.Journal of the American Heart Association · 2013Review
- Enhanced nanomagnetic gene transfection of human prenatal cardiac progenitor cells and adult cardiomyocytes.PloS one · 2013Article
- Catheter-based intramyocardial delivery (NavX) of adenovirus achieves safe and accurate gene transfer in pigs.PloS one · 2013Article
- AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Methods in cardiomyocyte isolation, culture, and gene transfer.Journal of molecular and cellular cardiology · 2011Review
- Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression.Interactive cardiovascular and thoracic surgery · 2010Article
- betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease.Journal of cardiovascular translational research · 2010Review
- Targeted gene therapy for the treatment of heart failure.The Canadian journal of cardiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Vector-mediated cardiac gene therapy holds tremendous promise as a translatable platform technology for treating many cardiovascular diseases. The ideal technique is one that is efficient and practical, allowing for global cardiac gene expression, while minimizing collateral expression in other organs. Here we survey the available in vivo vector-mediated cardiac gene delivery methods--including transcutaneous, intravascular, intramuscular, and cardiopulmonary bypass techniques--with consideration of the relative merits and deficiencies of each. Review of available techniques suggests that an optimal method for vector-mediated gene delivery to the large animal myocardium would ideally employ retrograde and/or anterograde transcoronary gene delivery,extended vector residence time in the coronary circulation, an increased myocardial transcapillary gradient using physical methods, increased endothelial permeability with pharmacological agents, minimal collateral gene expression by isolation of the cardiac circulation from the systemic, and have low immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.